BACKGROUND: During the period of 1996-1999, we prospectively monitored 243 Javanese adults and children after arriving in Papua, Indonesia, and microscopically documented each new case of malaria by active surveillance. METHODS: In a randomized, open-label, comparative malaria treatment trial, 72 adults and 50 children receivedchloroquinefor each incident case of malaria, and 74 adults and 47 children receivedmefloquine. RESULTS: Among 975 primary treatment courses, the cumulative 28-day curative efficacies were 26% and 82% for chloroquine against Plasmodium falciparum malaria and Plasmodium vivax malaria, respectively. Mefloquine cure rates were far superior (96% against P. falciparum malaria and 99.6% against P. vivax malaria). CONCLUSIONS:Mefloquine is a useful alternative treatment for P. vivax malaria and P. falciparum malaria in areas such as Papua, where chloroquine is still recommended as the first-line therapeutic agent.
RCT Entities:
BACKGROUND: During the period of 1996-1999, we prospectively monitored 243 Javanese adults and children after arriving in Papua, Indonesia, and microscopically documented each new case of malaria by active surveillance. METHODS: In a randomized, open-label, comparative malaria treatment trial, 72 adults and 50 children received chloroquine for each incident case of malaria, and 74 adults and 47 children received mefloquine. RESULTS: Among 975 primary treatment courses, the cumulative 28-day curative efficacies were 26% and 82% for chloroquine against Plasmodium falciparum malaria and Plasmodium vivaxmalaria, respectively. Mefloquine cure rates were far superior (96% against P. falciparum malaria and 99.6% against P. vivaxmalaria). CONCLUSIONS:Mefloquine is a useful alternative treatment for P. vivaxmalaria and P. falciparum malaria in areas such as Papua, where chloroquine is still recommended as the first-line therapeutic agent.
Authors: R Suwanarusk; M Chavchich; B Russell; A Jaidee; F Chalfein; M Barends; B Prasetyorini; E Kenangalem; K A Piera; U Lek-Uthai; N M Anstey; E Tjitra; F Nosten; Q Cheng; R N Price Journal: J Infect Dis Date: 2008-11-15 Impact factor: 5.226
Authors: Michael H Kinzer; Krisin Chand; Hasan Basri; Edith R Lederman; Augustina I Susanti; Iqbal Elyazar; George Taleo; William O Rogers; Michael J Bangs; Jason D Maguire Journal: Malar J Date: 2010-04-06 Impact factor: 2.979
Authors: Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey Journal: Am J Trop Med Hyg Date: 2007-12 Impact factor: 2.345